However, in vivo treatment with the AhR agonist Ficz alleviates the metabolic impairments (e.g., insulin and glucose dysmetabolism, intrahepatic lipid accumulation, and dyslipidemia) in both diet- and genetic-induced metabolic syndrome. Here, INS is linked to metabolic syndrome.